Glucotrack Announces Publication of Peer-Reviewed Study In The Journal of Diabetes Research Demonstrating Long-Term Accuracy and Stability of Continuous Blood Glucose Monitoring Technology
Glucotrack published a peer-reviewed study in the Journal of Diabetes Research demonstrating the long-term accuracy and stability of its implantable continuous blood glucose monitor in an ovine model. The study of 34 devices over up to 240 days showed a weighted average MARD of 6.8% with no device-related adverse safety events.
Key figures
- Drug Name
- Glucotrack CBGM
- Phase Of Trial
- Preclinical (Ovine model)
- Subjects count
- 17
- Devices implanted
- 34
- Iv tolerance tests
- 79
- Mard percent human
- 7.7
- Mard percent ovine
- 6.8
- Study duration days
- 240
- Data capture rate human percent
- 99
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.